SK bioscience and MSD Collaborate on Zaire Ebola Vaccine Development

SK bioscience is advancing the development of a vaccine for the Zaire ebolavirus through a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI). This initiative follows a funding agreement in which CEPI will provide up to USD 30 million to MSD, a global pharmaceutical company. The funding is intended to support critical research and development activities in partnership with SK bioscience and Hilleman Laboratories, a joint venture between MSD and Wellcome.

The collaboration focuses on enhancing MSD’s existing Zaire ebolavirus vaccine, which is already prequalified by the World Health Organization (WHO). The project aims to update the complex manufacturing process that requires ultra-low temperature storage, a significant obstacle in remote areas that frequently experience Ebola outbreaks. By improving manufacturing yield and increasing the vaccine’s thermostability, the initiative seeks to create a more affordable and accessible supply of the vaccine, pending regulatory approval.

Strengthening Global Health Preparedness

Hilleman Laboratories will lead the clinical development for the updated vaccine, while SK bioscience, in collaboration with IDT Biologika, will refine the drug substance manufacturing process. As an implementation partner in this CEPI-backed public health initiative, SK bioscience plans to leverage its extensive vaccine manufacturing expertise to enhance the affordability and long-term sustainability of vaccines in low- and middle-income countries.

The Zaire ebolavirus is known for causing unpredictable outbreaks, with a survival rate of approximately 50%. Recent incidents in the Democratic Republic of the Congo and surrounding regions have highlighted the ongoing global threat posed by this virus, particularly in areas with limited healthcare resources and infrastructure.

Dr. Richard Hatchett, CEO of CEPI, emphasized the significance of this partnership, stating, “In a single decade, the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks. CEPI’s support will help enable a sustainable and accessible supply of MSD’s Zaire ebolavirus vaccine for years to come at a more affordable price.”

Commitment to Public Health

Jaeyong Ahn, CEO of SK bioscience, reiterated the importance of global collaboration in addressing infectious diseases like Ebola. He stated, “Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire ebolavirus vaccine manufacturing and supply, contributing meaningfully to global health preparedness.”

SK bioscience has a proven track record of working with global health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). By utilizing its integrated capabilities in development, manufacturing, and supply, the company aims to strengthen its position as a global partner in public health initiatives.

Founded with a commitment to equitable access to vaccines, SK bioscience leverages cutting-edge technologies to promote health worldwide. The company’s collaboration with governments, regulatory agencies, and healthcare providers demonstrates its dedication to delivering high-quality vaccines and enhancing public health solutions for those in need.